What is the Frequency of Opioid Abuse in Cancer Patients?

With the opioid crisis claiming so many lives, physicians need to be especially careful prescribing these drugs. However, for many patients with cancer who are in a lot of pain, opioids can be a necessary part of treatment. So how can physicians determine predictors and frequency of opioid abuse in this population? A study now published in JAMA Oncology found that marital status, higher levels of pain, high scores on the Screener and Opioid Assessment for Patients with Pain (SOAPP), and morphine...
Continue reading

Hagop Kantarjian, MD: Inotuzumab Ozogamicin for Relapsed/Refractory Ph-Positive Acute Lymphoblastic Leukemia

Among patients with relapsed/refractory acute lymphoblastic leukemia (ALL), those with Philadelphia chromosome (Ph)-positive disease experience a higher rate of relapse and poorer chances of long-term survival. According to results of the phase 3 INO-VATE trial recently published in Cancer, inotuzumab ozogamicin, a humanized anti-CD22 monoclonal antibody, achieved high rates of response, remission, and progression-free survival in patients with this disease. In this interview with i3 Health, Hag...
Continue reading

Pralsetinib Approved For Patients with Advanced or Metastatic RET-Altered Medullary Thyroid Cancer

The FDA has approved pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) that requires systemic therapy and for patients with RET fusion-positive thyroid cancer who require systemic therapy and whose disease is refractory to radioactive iodine therapy. The approval was based on ARROW (NCT03037385), an open label, multi-cohort phase 1/2 clinical trial led by f...
Continue reading

Lung Cancer Screening Adherence After Baseline Screening Is Lower Than Reported

Patients who undergo baseline lung cancer screening are less likely to adhere to screening recommendations compared with the screening rates of patients who participate in randomized clinical trials, according to a meta-analysis now published in JAMA Network Open. Undergoing regular cancer screening has been shown to reduce the risk of cancer mortality. Data from the 2018 National Health Interview Survey found that approximately 70% of eligible women underwent breast cancer screening within the ...
Continue reading

Venetoclax Combo Approved for Older Patients With Acute Myeloid Leukemia

The FDA has now granted full approval to venetoclax (Venclexta®, AbbVie Inc. and Genentech Inc.) in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for patients with previously untreated acute myeloid leukemia (AML) who are at least 75 years of age or who have comorbidities that prevent them from receiving intensive induction chemotherapy. Previously, this venetoclax combination therapy was granted accelerated approval in 2018 for use in this same patient population. The ...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.